Henry Schein Q3 2026 Earnings Beat Fueled by Dental Rebound and Guidance Raise

As seen on the 24/7 Wall St. homepage on November 3, 2026.

HSIC Henry Schein
Q3 2026
EPS
$1.56
est $1.36 +14.9%
Revenue
$3.47B
est $3.48B -0.1%

Henry Schein raised full-year adjusted EPS guidance to $5.50 to $5.56 from $5.29 to $5.39, signaling the dental recovery is taking hold. A tariff refund benefit flattered the quarter's earnings beat.

Continue ReadingShow less

Henry Schein reported adjusted non-GAAP diluted EPS of $1.56 for Q3 2026, beating the consensus estimate. Revenue was essentially in line with expectations.

A $0.19 per diluted share net benefit from IEEPA tariff refunds played a meaningful role in the earnings beat, so investors are right to look past the headline number. Stripping out that item, underlying EPS merely matched the consensus estimate.

The more durable signal is what happened in U.S. dental merchandise, where sales rose 8.6%, with management attributing the gain primarily to volume rather than pricing. Adjusted EBITDA climbed and margin expanded, signs that the dental recovery is generating real operating leverage.

Sponsored

Confident in the trajectory, CEO Fred Lowery raised full-year 2026 non-GAAP diluted EPS guidance to $5.50 to $5.56, while keeping total sales growth guidance steady and upgrading the adjusted EBITDA growth outlook to high-single-digits. The guidance explicitly assumes no significant further tariff refunds or remeasurement gains in Q4, so the raised bar rests on underlying business performance.

Henry Schein repurchased about 1.4 million shares in the quarter, and roughly $330 million remained authorized for future buybacks at quarter end, adding another layer of support for the share price heading into the final stretch of 2026.

Mentioned: HSIC